Zanaflex is a brand name of tizanidine, approved by the FDA in the following formulation(s):
ZANAFLEX (tizanidine hydrochloride - capsule; oral)
Manufacturer: ACORDA
Approval date: August 29, 2002
Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [RLD][AB]
ZANAFLEX (tizanidine hydrochloride - tablet; oral)
Manufacturer: ACORDA
Approval date: November 27, 1996
Strength(s): EQ 4MG BASE [RLD][AB]
Has a generic version of Zanaflex been approved?
A generic version of Zanaflex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zanaflex and have been approved by the FDA:
tizanidine hydrochloride capsule; oral
Manufacturer: APOTEX INC
Approval date: February 3, 2012
Strength(s): EQ 2MG BASE [AB], EQ 4MG BASE [AB], EQ 6MG BASE [AB]
tizanidine hydrochloride tablet; oral
Manufacturer: ALPHAPHARM
Approval date: December 16, 2003
Strength(s): EQ 4MG BASE [AB]
Manufacturer: APOTEX
Approval date: January 16, 2004
Strength(s): EQ 4MG BASE [AB]
Manufacturer: CARACO
Approval date: September 29, 2003
Strength(s): EQ 4MG BASE [AB]
Manufacturer: COREPHARMA
Approval date: October 11, 2002
Strength(s): EQ 4MG BASE [AB]
Manufacturer: DR REDDYS LABS INC
Approval date: July 3, 2002
Strength(s): EQ 4MG BASE [AB]
Manufacturer: MYLAN
Approval date: March 28, 2003
Strength(s): EQ 4MG BASE [AB]
Manufacturer: SANDOZ
Approval date: June 27, 2002
Strength(s): EQ 4MG BASE [AB]
Manufacturer: TEVA
Approval date: July 3, 2002
Strength(s): EQ 4MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zanaflex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method of reducing somnolence in patients treated with tizanidine
Patent 6,455,557
Issued: September 24, 2002
Inventor(s): Cara A.; Pellegrini & Paul; Stark
Assignee(s): Elan Pharmaceuticals, Inc.
An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.Patent expiration dates:
- November 28, 2021
- November 28, 2021
See also...
- Zanaflex Consumer Information (Drugs.com)
- Zanaflex Consumer Information (Wolters Kluwer)
- Zanaflex Consumer Information (Cerner Multum)
- Zanaflex Advanced Consumer Information (Micromedex)
- Zanaflex AHFS DI Monographs (ASHP)
- Tizanidine Consumer Information (Drugs.com)
- Tizanidine Consumer Information (Wolters Kluwer)
- Tizanidine Consumer Information (Cerner Multum)
- Comfort Pac w/Tizanidine Advanced Consumer Information (Micromedex)
- Zanaflex Capsule Advanced Consumer Information (Micromedex)
- Tizanidine Advanced Consumer Information (Micromedex)
- Tizanidine Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment